Breztri Aerosphere package

Notice: Product images are for illustration purposes only and may differ from the medication you receive. Packaging and appearance may vary depending on the country of origin, and generic medications may be supplied by different manufacturers. The medication, strength, and active ingredients will match your prescription. At the Canadian Pharmacy Store we prioritize your health and safety by working with licensed pharmacy partners to provide safe, high-quality medications.

Breztri Aerosphere (Budesonide / Glycopyrrolate / Formoterol Fumarate)

Breztri Aerosphere

Budesonide, Glycopyrrolate, Formoterol Fumarate

Sourced from Canada Source: Canada
Prescription Required
Select product strength & quantity:
Select Strength & Quantity

Choose the strength, form, and package size that match your prescription.

Send Your Prescription

Upload your prescription online, request a transfer, or have your doctor fax us.

Pharmacist Review & Delivery

Reviewed by a licensed pharmacist and shipped to your U.S. address with tracking. Shipping details.

Description

Breztri Aerosphere (budesonide, glycopyrrolate and formoterol) is a triple-combination maintenance inhaler listed in our Respiratory medications and inhalers directory and prescribed for specified asthma or reversible-airway conditions and chronic obstructive pulmonary disease (1.1) (2.1). Administered via oral inhalation, Breztri Aerosphere is available for delivery to U.S. residents through Canadian Pharmacy Store with a valid prescription. Review the clinical fact table, dosage directions, cautions, drug interactions, side effects, and official regulatory sources below.

Breztri Aerosphere is a medication containing the active pharmaceutical ingredient budesonide, glycopyrrolate and formoterol, classified pharmacologically as a triple-combination maintenance inhaler (2.1). It is clinically indicated for the management of specified asthma or reversible-airway conditions and chronic obstructive pulmonary disease as part of a comprehensive treatment plan supervised by a licensed healthcare provider (2.1).

Within the Respiratory medications and inhalers section of our catalogue, patients and prescribers frequently review Breztri Aerosphere alongside related therapies such as Pulmicort Nebuamp (Budesonide), Pulmicort Turbuhaler (Budesonide), Symbicort (Budesonide / Formoterol Fumarate Dihydrate), and Entocort (Budesonide).

Official Indications and Usage

Breztri Aerosphere is a combination of budesonide, an inhaled corticosteroid (ICS); glycopyrrolate, an anticholinergic; and formoterol fumarate, a long-acting beta-2 adrenergic agonist (LABA), indicated for (1.1):

  • The maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.
  • The maintenance treatment of asthma in adult and pediatric patients 12 years of age and older.

Limitations of use: Not indicated for the relief of acute bronchospasm.

Mechanism of Action and Pharmacology

Breztri Aerosphere Breztri Aerosphere contains budesonide, glycopyrrolate, and formoterol fumarate. The mechanism of action described below for the individual components applies to Breztri Aerosphere. These drugs represent three different classes of medications (a synthetic corticosteroid, an anticholinergic, and a long-acting selective beta 2 -adrenoceptor agonist) that have different effects on clinical physiology and inflammatory indices of COPD and asthma. Budesonide Budesonide is an anti-inflammatory corticosteroid that exhibits potent glucocorticoid activity and weak mineralocorticoid activity. In standard in vitro and animal models, budesonide has approximately a 200-fold higher affinity for the glucocorticoid receptor and a 1000-fold higher topical anti-inflammatory potency than cortisol (rat croton oil ear edema assay). (1.1) (3.1)

What is Asthma?

Asthma involves inflammation and narrowing of the airways. Controller and quick-relief treatments have distinct roles in an individualized action plan. Explore related medications below and discuss treatment options with your healthcare provider. Read our complete Asthma condition guide for appointment questions and related therapies (4.1).

What is COPD?

Chronic obstructive pulmonary disease causes persistent breathing limitation. Treatment can include inhaled medicines, smoking cessation, rehabilitation, and an exacerbation plan. Explore related medications below and discuss treatment options with your healthcare provider. Read our complete COPD condition guide for appointment questions and related therapies (4.1).

Ordering Breztri Aerosphere from Canada for U.S. Delivery

U.S. patients can order Breztri Aerosphere (Budesonide, Glycopyrrolate, Formoterol) in U.S. dollars with a valid prescription from a U.S.-licensed clinician. Your card is only charged after your prescription passes pharmacist safety checks and is ready to ship.

Step 1

Send Your Prescription

Step 2

Pharmacist Safety Check

  • Multi-point dosing and interaction review completed in under 1 business day.
  • Mandatory licensed pharmacist consultation via phone, voicemail, or text before dispatch.
  • Verified under our Pharmacy Safety Standards.
Step 3

$14.99 USD Tracked Parcel

  • Packed in discreet protective packaging for a flat $14.99 USD per order ($29.99 if combined with cold-chain).
  • Tracked via Canada Post and USPS: 3 to 7 business days from Canada (7 to 14 days from international partners).
  • Review full shipping and delivery details.
Step 4

U.S. Street Delivery & Payment

  • Delivered to any physical U.S. street address with signature upon delivery (no P.O. Boxes).
  • You see and approve the country of origin upfront before your card is charged.
  • Report any delayed or damaged parcel within 48 hours for prompt resolution.

Fact Table

Clinical Specification Details
Brand / Product Name Breztri Aerosphere
Chemical / Generic Name Budesonide, Glycopyrrolate And Formoterol
Pharmacological Class Triple-combination maintenance inhaler
Therapeutic Category Respiratory medications and inhalers
Same-Ingredient Catalogue Entries Pulmicort Nebuamp (Budesonide), Pulmicort Turbuhaler (Budesonide), Symbicort (Budesonide / Formoterol Fumarate Dihydrate), Entocort (Budesonide)
Molecular Formula C25H34O6 (3.1)
Molecular Weight 430.5 g/mol (3.1)
Protein Binding ~86% (1.1)
Elimination Half-Life ~5 hours (1.1)
Time to Peak Plasma Level (Tmax) 20 to 40 minutes (2.1)
Legal Status Rx-Only (Prescription Required)
Regulatory Reference Authorities U.S. FDA (DailyMed), Health Canada (DPD), NIH PubChem, NLM MedlinePlus
Routes of Administration Oral Inhalation
Available Dosage Strengths 160/5/7.2
Dosage Form Inhaler
Primary Indications Specified Asthma Or Reversible-Airway Conditions And Chronic Obstructive Pulmonary Disease
Pregnancy & Breastfeeding Consult Doctor / Prescriber before use
PubChem CID 5281004
Official DailyMed SetID 715433dc-cb2b-43ea-b6df-c5b4177adc6c
Catalogue Index Links Letter B Index · All Medications · All Categories

Directions

Dosage and Administration Overview

  • For oral inhalation only.
  • Prime Breztri Aerosphere before first time use and re-prime if not used for more than 7 days.
  • Maintenance treatment of COPD: 2 inhalations of Breztri Aerosphere 160 mcg/9 mcg/4.8 mcg twice daily administered by oral inhalation. (1.1)

Presentations and Strengths

Inhalation aerosol: a pressurized metered dose inhaler with an attached dose indicator, a yellow plastic actuator, a white mouthpiece, and a grey plastic dust cap that delivers a combination of (1.1):

  • 160 mcg/9 mcg/4.8 mcg (budesonide 160 mcg, glycopyrrolate 9 mcg, and formoterol fumarate 4.8 mcg) per inhalation.

Administration Guidance

Inhale at the same time(s) each day using the prescribed inhaler or nebulizer device as directed on your prescription label (1.1). If your medication contains an inhaled corticosteroid, rinse your mouth with water and spit out without swallowing after each dose to help prevent oral thrush.

Missed Dose Guidance

If you miss a scheduled dose of Breztri Aerosphere, follow the missed-dose instructions in the official patient leaflet or ask your pharmacist. Do not double the next dose to make up for a missed dose (2.1).

Ingredients

Active Pharmaceutical Ingredient

The active ingredient in Breztri Aerosphere is budesonide, glycopyrrolate and formoterol (molecular formula C25H34O6, molecular weight 430.5 g/mol) (1.1) (3.1). Other catalogue entries containing budesonide include Pulmicort Nebuamp (Budesonide), Pulmicort Turbuhaler (Budesonide), Symbicort (Budesonide / Formoterol Fumarate Dihydrate), and Entocort (Budesonide).

Excipients and Formulation Carriers

Film coatings, stabilizers, and inactive carriers vary by strength and manufacturer presentation. If you have a known allergy to lactose, dyes, sulfites, or specific preservatives, ask our pharmacist to check the exact excipient list for your selected package (2.1).

Cautions and important safety information

Contraindications

Breztri Aerosphere is contraindicated in the following conditions (1.1):

  • Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required.
  • Hypersensitivity to budesonide, glycopyrrolate, formoterol, or any of the excipients.

Key Clinical Precautions

Before starting or continuing Breztri Aerosphere, discuss your complete medical history with your healthcare provider. Key clinical cautions include (1.1):

  • Increased susceptibility to infection: Therapies that modulate immune or metabolic pathways can increase the risk of bacterial, mycotic (fungal), viral, or opportunistic infections. Report fever, persistent cough, painful urination, or localized infection promptly.
  • Diabetic ketoacidosis (DKA): Ketoacidosis, a serious condition requiring urgent hospitalization, has been reported even when blood glucose readings are below 250 mg/dL. Risk factors include acute febrile illness, reduced caloric or fluid intake, pancreatic disorders, surgery, and insulin dose reduction.
  • Hypersensitivity and anaphylaxis: Serious allergic reactions, including anaphylaxis, angioedema, and severe rash, have been reported. Discontinue use and seek immediate medical care if swelling of the face, lips, tongue, or throat or difficulty breathing occurs.
  • Angioedema: Swelling of the face, extremities, lips, tongue, glottis, or larynx can occur at any time during treatment. Airway-involving angioedema requires emergency medical intervention.
  • Hypotension and volume depletion: Intravascular volume contraction can cause symptomatic low blood pressure, orthostatic dizziness, or fainting, especially in older adults, patients with impaired renal function, or those taking diuretics. Ensure adequate hydration before and during therapy.
  • Blood pressure elevation: Monitor blood pressure regularly during treatment and inform your clinician if sustained increases occur.

Pregnancy, Lactation, and Special Populations

There are no adequate and well-controlled studies with Breztri Aerosphere or with two of its individual components, glycopyrrolate or formoterol fumarate, in pregnant women to inform a drug-associated risk; however, studies are available for the other component, budesonide. In animal reproduction studies, budesonide alone, administered by the subcutaneous route, caused structural abnormalities, was embryocidal, and reduced fetal weights in rats and rabbits at 0.3 and 0.75 times maximum recommended human daily inhaled dose (mrhdid), respectively, but these effects were not seen in rats that received inhaled doses up to 4 times the mrhdid. (1.1)

Interactions

Official Drug Interaction Overview

No formal drug interaction studies have been performed with Breztri Aerosphere (1.1):

  • Strong cytochrome P450 3A4 inhibitors (e.g. Ritonavir): Use with caution. May cause systemic corticosteroid effects.
  • Other adrenergic drugs may potentiate effect: Use with caution.
  • Diuretics, xanthine derivatives or steroids may potentiate hypokalemia or ECG changes. Use with caution.
  • Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of formoterol fumarate on cardiovascular system.
  • Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm.
  • Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of Breztri Aerosphere with other anticholinergic-containing drugs.

Important Interaction Categories

Concomitant use of Breztri Aerosphere with certain prescription medications, over-the-counter drugs, or supplements can alter how the medication works or increase the risk of side effects. Important interaction categories to review with your prescriber and pharmacist include (2.1):

  • Potassium supplements, potassium-sparing diuretics (such as Aldactone (Spironolactone), eplerenone, triamterene, or amiloride), and salt substitutes: Concomitant use can lead to clinically significant hyperkalemia (elevated serum potassium). Regular electrolyte monitoring is recommended.
  • Monoamine oxidase inhibitors (MAOIs, such as phenelzine, tranylcypromine, selegiline, or linezolid): Concomitant use or use within 14 days of stopping an MAOI can cause severe drug interactions, including hypertensive crisis, serotonin syndrome, or enhanced hypoglycemic and central nervous system effects.
  • Strong CYP3A4 inhibitors and inducers (such as ketoconazole, itraconazole, clarithromycin, ritonavir, rifampin, carbamazepine, phenytoin, or St. John’s wort): Co-administration with strong CYP3A4 inhibitors can significantly increase plasma concentrations and side-effect risk, whereas CYP3A4 inducers can decrease systemic exposure and reduce efficacy.

Side effects

Like all medications, Breztri Aerosphere can cause side effects, although not everyone experiences them. Commonly reported side effects in clinical trials and official labeling include (1.1):

  • Nausea (feeling sick): Often mild to moderate and most noticeable when starting therapy or increasing the dose; eating smaller, lower-fat meals and avoiding lying down immediately after eating may help reduce nausea.
  • Diarrhea (loose stools): Maintain adequate fluid and electrolyte intake; contact your prescriber if diarrhea is severe or persistent.
  • Headache: Commonly reported during initial treatment; often improves as your body adjusts to the medication.
  • Dizziness or lightheadedness: May occur especially when standing up quickly from a sitting or lying position (orthostatic changes); rise slowly and stay well hydrated.
  • Insomnia or sleep disturbances: Taking morning doses earlier in the day (if consistent with your prescription) may reduce nighttime restlessness.
  • Xerostomia (dry mouth): Sipping water or using sugar-free lozenges can help relieve oral dryness.

Clinical Trial and Postmarketing Adverse Reactions

  • Serious asthma-related events - hospitalizations, intubations, death.
  • Oropharyngeal candidiasis infection.
  • Increased risk of pneumonia in COPD.
  • Immunosuppression and risk of infections.
  • Hypercorticism and adrenal suppression.
  • Paradoxical bronchospasm.
  • Hypersensitivity reactions including anaphylaxis.
  • Cardiovascular effects.
  • Reduction in bone mineral density.
  • Growth effects in pediatric patients.
  • Worsening of narrow-angle glaucoma and cataracts.
  • Worsening of urinary retention Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. (1.1)

When to Seek Immediate Medical Attention

Contact your physician or seek urgent medical care if you experience signs of a severe allergic reaction (hives, difficulty breathing, or swelling of the face, lips, tongue, or throat), severe dizziness or fainting, unexplained severe pain, or any sudden change in your clinical symptoms (2.1).

Storage and handling

Aerosphere Inhalation Aerosol (1.1):

  • Breztri Aerosphere is supplied as a pressurized aluminum canister with an attached dose indicator, a yellow plastic actuator, a white mouthpiece, and a grey plastic dust cap.
  • Each canister of Breztri Aerosphere is packaged in a foil laminate pouch with a desiccant sachet and is placed into a carton.
  • Each carton contains one canister and Patient Information. Breztri Aerosphere is available as presented in Table 7.

Store Breztri Aerosphere in its original container at controlled room temperature away from excess heat, direct light, and moisture (such as bathroom cabinets), and keep out of reach of children and pets (1.1).

Frequently Asked Questions About Breztri Aerosphere

What is Breztri Aerosphere and what active ingredient does it contain?

Breztri Aerosphere is a triple-combination maintenance inhaler containing the active pharmaceutical ingredient budesonide, glycopyrrolate and formoterol (chemical formula C25H34O6). It is supplied for oral inhalation administration and requires a valid prescription where applicable.

How does Breztri Aerosphere work in the body?

Breztri Aerosphere Breztri Aerosphere contains budesonide, glycopyrrolate, and formoterol fumarate. The mechanism of action described below for the individual components applies to Breztri Aerosphere. These drugs represent three different classes of medications (a synthetic corticosteroid, an anticholinergic, and a long-acting selective beta 2 -adrenoceptor agonist) that have different effects on clinical physiology and inflammatory indices of COPD and asthma.

What conditions is Breztri Aerosphere prescribed to treat?

Breztri Aerosphere is primarily indicated for specified asthma or reversible-airway conditions and chronic obstructive pulmonary disease. Your prescribing clinician determines the appropriate indication, strength, and treatment duration based on your individual diagnosis and medical history.

How should I take or use Breztri Aerosphere?

Follow the exact dosage, frequency, and administration instructions printed on your prescription label. Breztri Aerosphere is administered via the oral inhalation route. Inhale or administer it consistently at the same time(s) as directed, and never adjust your dose or stop therapy without speaking with your prescriber.

What are the most common side effects of Breztri Aerosphere?

Commonly reported side effects of Breztri Aerosphere include feeling sick, loose stools, headache, dizziness, difficulty sleeping, and dry mouth. Most mild side effects improve as your body adjusts to treatment, but you should notify your doctor or pharmacist if symptoms persist or worsen.

What medications or substances can interact with Breztri Aerosphere?

Important interaction categories for Breztri Aerosphere include potassium-containing products, monoamine oxidase inhibitors, and medicines that strongly affect CYP3A enzymes. Always share a complete list of your prescription drugs, over-the-counter medicines, vitamins, and herbal supplements with your pharmacist before starting treatment.

Can Breztri Aerosphere be used during pregnancy or breastfeeding?

If you are pregnant, planning to become pregnant, or breastfeeding, consult your prescribing physician before using Breztri Aerosphere to weigh the clinical benefits and potential risks.

Do I need a prescription to buy Breztri Aerosphere online from Canada?

Yes. A valid prescription written by a U.S.-licensed physician, nurse practitioner, or physician assistant is required to buy Breztri Aerosphere (Budesonide, Glycopyrrolate, Formoterol) through our licensed Canadian pharmacy partners. Valid prescriptions go through multiple safety checks in less than 1 business day, followed by a mandatory request to speak with a licensed pharmacist for a consultation (watch your phone, voicemails, and text messages).

Does Breztri Aerosphere have a generic equivalent (Budesonide, Glycopyrrolate, Formoterol) at a Canada pharmacy?

Currently, Breztri Aerosphere (Budesonide, Glycopyrrolate, Formoterol) is dispensed in our catalogue as a brand-name formulation. Check our Budesonide, Glycopyrrolate, Formoterol active ingredient hub for updates as licensed generic presentations become available.

How is Breztri Aerosphere shipped to U.S. residents, and how much does shipping cost?

Breztri Aerosphere ships in discreet protective packaging at a flat rate of $14.99 USD per order via Canada Post and USPS with full tracking (if combined in the same order with a cold-chain item, total shipping is $29.99 USD in a larger container). Once your valid prescription passes safety checks (<1 business day) and you respond to the mandatory licensed pharmacist consultation request via phone, voicemail, or text message, delivery takes 3 to 7 business days from Manitoba, Canada (or 7 to 14 business days from licensed partner pharmacies in the UK, Singapore, and Mauritius). You see and choose the country of origin before you pay, and your Visa, Mastercard, or Discover card is only charged when your order is ready to ship.

How can I send or transfer my Breztri Aerosphere prescription, or ask about an unlisted strength?

You can upload a clear photo or PDF of your Breztri Aerosphere prescription online, request a prescription transfer or direct prescriber coordination from our team, or have your prescriber fax the prescription directly to (844) 666 – 6819. You may order up to a 90-day personal-use supply per shipment. If you do not see your exact prescribed strength or manufacturer listed, call 1-888-868-1920 and our staff will check availability across our licensed pharmacy partners.

References & Official Sources

Clinical, pharmacological, and safety facts for Breztri Aerosphere (Budesonide / Glycopyrrolate / Formoterol Fumarate) are compiled directly from official regulatory prescribing labels and primary biomedical databases:

  1. (1.1) Breztri Aerosphere (Budesonide / Glycopyrrolate / Formoterol Fumarate) — Official FDA Prescribing Information (DailyMed). U.S. National Library of Medicine / U.S. Food and Drug Administration (DailyMed). Official U.S. FDA / DailyMed Structured Product Labeling (SPL). (Accessed 2026-10-29).
  2. (2.1) Health Canada Drug Product Database (DPD), Authorized Product Records. Health Canada / Government of Canada. Health Canada Drug Product Database & Official Product Monograph. (Accessed 2026-10-28).
  3. (3.1) PubChem Compound Summary for cid 5281004 (Budesonide). National Center for Biotechnology Information (NCBI), U.S. National Library of Medicine. Official regulatory & clinical reference. (Accessed 2026-10-29).
  4. (4.1) MedlinePlus Medical Encyclopedia: Asthma. MedlinePlus / National Library of Medicine. U.S. National Library of Medicine, MedlinePlus Drug & Health Information. (Accessed 2026-10-29).
  5. (5.1) MedlinePlus Medical Encyclopedia: COPD. MedlinePlus / National Library of Medicine. U.S. National Library of Medicine, MedlinePlus Drug & Health Information. (Accessed 2026-10-29).

Related Condition Guides

Related Guides

Call 1-888-868-1920Help